Sankyo Co., Ltd. / Daiichi Pharmaceutical Co., Ltd.

Cardiovascular and Oncology Therapeutics (Diversified Pharma)

Disease Overview

Sankyo and Daiichi were two century-old Japanese pharmaceutical companies whose combined R&D portfolios spanned cardiovascular disease (Sankyo's olmesartan/Benicar, pravastatin/Mevalotin), oncology, antibiotics, and metabolic disease. The merger created a single Japanese R&D-driven pharma with the scale needed to compete globally in specialty therapeutics rather than commodity primary care.

Strategic Rationale & Outcome

By 2005, Japan's pharma sector faced consolidation pressure from Western majors expanding into Asia and from domestic price-cut policies. The Sankyo–Daiichi joint share transfer formed Daiichi Sankyo as 'second-largest pharmaceutical company in Japan', with former Sankyo holders owning ~58% and Daiichi holders ~42% post-close. Competing combinations of the era — Astellas (Yamanouchi+Fujisawa, 2005), Mitsubishi Tanabe (2007), and Dainippon Sumitomo (2005) — defined a wave of defensive Japanese mega-mergers. Daiichi Sankyo's bet on global specialty scale paid off unevenly: the 2008 Ranbaxy acquisition was written down for ~$5B in 2014, but the company's pivot to oncology and ADCs ultimately produced Enhertu (trastuzumab deruxtecan, partnered with AstraZeneca) and Vanflyta (quizartinib for FLT3-mutant AML, US launch August 2023). FY2022 revenue reached 'JPY 1,278 billion', and Enhertu alone was guided to ~$2.61B for FY2023. Forward-looking close: A decade and a half after close, the merger's strategic value crystallized not in the legacy CV/PCP businesses but in the oncology pipeline assembled under combined R&D, with Enhertu becoming a multi-billion-dollar HER2-low franchise and Vanflyta entering a competitive AML market against Astellas's Xospata and Bristol Myers Squibb's Idhifa.